Quantitative analysis of11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function

Journal of Nuclear Medicine

Volumn 47, Issue 9, 2006, Pages 1531-1537

  Ikoma, Yoko ^a   Takano, Akihiro ^a   Ito, Hiroshi ^a   Kusuhara, Hiroyuki ^b   Sugiyama, Yuichi ^b   Arakawa, Ryosuke ^a,c   Fukumura, Toshimitsu ^a   Nakao, Ryuji ^a   Suzuki, Kazutoshi ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

11C verapamil; Blood brain barrier; P glycoprotein; PET; Transfer rate constant

Indexed keywords

CARBON 14; DRUG METABOLITE; GLYCOPROTEIN P; VERAPAMIL; CARBON; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; COMPARTMENT MODEL; CORRELATION ANALYSIS; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; NONLINEAR SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; SIMULATION; ALGORITHM; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; ISOTOPE DILUTION ASSAY; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING;

ADULT; ALGORITHMS; BLOOD-BRAIN BARRIER; CARBON RADIOISOTOPES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; RADIOISOTOPE DILUTION TECHNIQUE; RADIOPHARMACEUTICALS; VERAPAMIL;

EID: 33750588234     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735-7738.
2. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86:695-698.
3. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev. 2000;26:449-462.
4. Bart J, Groen HJ, van der Graaf WT, et al. An oncological view on the bloodtestis barrier. Lancet Oncol. 2002;3:357-363.
5. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
6. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371-1388.
7. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier. Part 1. Drug Discov Today. 2001;6:150-156.
8. Hirrlinger J, Konig J, Dringen R. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem. 2002;82:716-719.
9. Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002;12:535-541.
10. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
11. Elsinga PH, Franssen EJ, Hendrikse NH, et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med. 1996;37:1571-1575.
12. Hendrikse NH, Schinkel AH, de Vries EG, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol. 1998;124:1413-1418.
13. Hendrikse NH, de Vries EG, Eriks-Fluks L, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 1999;59:2411-2416.
14. 11C]verapamil kinetics in human tissues. Eur J Clin Pharmacol. 2001;56:827-829.
15. 11C-methyl]-(-)-cocaine PET studied in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
16. 11C]verapamil measured with PET. Neuroimage. 2003;20:1775-1782.
17. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des. 2004;10:1493-1503.
18. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77:503-514.
19. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176-179.
20. 11C]verapamil. J Pharmacol Exp Ther. 2006;316:647-653.
21. 11C]verapamil [abstract]. J Nucl Med. 2003;44(suppl):1303P.
22. 11C]verapamil. Appl Radiat Isot. 2002;57:505-507.
23. Yasuno F, Hasnine AH, Suhara T, et al. Template-based method for multiple volumes of interest of human brain PET images. Neuroimage. 2002;6:577-586.
24. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovander B. Automated blood sampling systems for positron emission tomography. IEEE Trans Nucl Sci. 1988;35:703-707.
25. Takei M, Kida T, Suzuki K. Sensitive measurement of positron emitters eluted from HPLC. Appl Radiat Isot. 2001;55:229-234.
26. 18F]fluoro-DOPA in human positron emission tomographic studies. J Cereb Blood Flow Metab. 1991;11:898-913.
27. 18F]fluoro-DOPA and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab. 1993;13:43-56.
28. 11C]PK11195 brain studies. J Cereb Blood Flow Metab. 2005;25:842-851.
29. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, Hanano M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci. 1988;77:200-207.
30. Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab. 2001;21:307-320.
31. Ikoma Y, Toyama H, Uemura K, Kimura Y, Senda M, Uchiyama A. Evaluation of the reliability of parameter estimates in the compartment model analysis by using the fitting error. In: Gjedde A, Hansen SB, Knudsen GM, Paulson OB, eds. Physiological Imaging of the Brain with PET. New York, NY: Academic Press; 2001:91-95.
32. 11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol. 2005;32:87-93.
33. Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000;293:376-382.